Preferences for Lisdexamfetamine vs Cognitive-Behavioral Therapy for Binge-Eating Disorder
The Journal of Clinical Psychiatry · 2025
DOI: 10.4088/jcp.24m15552 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Psychiatry, 2025. Verfasst von Sydney Yurkow und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut. Hauptthemen laut MEDLINE: Lisdexamfetamine Dimesylate, Binge-Eating Disorder, Cognitive Behavioral Therapy, Patient Preference.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut.
- Corresponding Author: Carlos M. Grilo, PhD, Yale University School of Medicine, 300 George St (9th floor), New Haven, CT 06511 (carlos.grilo@yale.edu).
Zitieren
APA
Yurkow, S., Ivezaj, V., Pittman, B., & Grilo, C. M. (2025). Preferences for Lisdexamfetamine vs Cognitive-Behavioral Therapy for Binge-Eating Disorder. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.24m15552
Vancouver
Yurkow S, Ivezaj V, Pittman B, Grilo CM. Preferences for Lisdexamfetamine vs Cognitive-Behavioral Therapy for Binge-Eating Disorder. The Journal of Clinical Psychiatry. 2025. doi:10.4088/jcp.24m15552
BibTeX
@article{Yurkow2025,
author = {Yurkow, Sydney and Ivezaj, Valentina and Pittman, Brian and Grilo, Carlos M},
title = {Preferences for Lisdexamfetamine vs Cognitive-Behavioral Therapy for Binge-Eating Disorder},
journal = {The Journal of Clinical Psychiatry},
year = {2025},
doi = {10.4088/jcp.24m15552}
}
EUVIMED